Abstract Library

#4556 Optimising the establishment of patient-derived models for neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are clinically and molecularly diverse, with limited understanding of their tumour biology. Efforts to develop patient-derived models have been unsuccessful, highlighting an urgent need for accurate models to support fundamental research.

Conference:

Presenting Author: Hernández Llorens M

Authors: Hernández-Llorens M, Baena-Moreno M, Lamas-Paz A, Sarmentero J, Anton-Pascual B,

Keywords: patient-derived model, organoids, PDXs, Growth factor,

#4396 Hypoxic microenvironment in neuroendocrine tumours

Introduction: The hypoxic microenvironment is a hallmark of many solid tumours, including neuroendocrine tumours (NETs). Hypoxia plays a crucial role in tumour progression, metastasis, and therapy resistance. However, the specific mechanisms by which hypoxia influences NET behaviour remain poorly understood.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Ye M, Chen J, Tang Q,

Keywords: Neuroendocrine tumour, hypoxia, HIF-1α, VEGF, mTOR, PI3K/AKT, drug resistance, EMT,

#4337 Differences in plasma concentrations of selected growth factors in endocrine neoplasms – A pilot study

Introduction: Serum levels of growth factors associated with endocrine tumours may be potentially useful in detecting their recurrence.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Kurzynska A, Morawiec-Slawek K, Stefanska A, Kolasa M,

Keywords: growth factor, endocrine tumour, TNF-α, Fascin, recurrence risk,

#3987 m6A modifications promote the invasion and metastasis of pancreatic neuroendocrine neoplasms by activating the Integrin/FAK signalling pathway via TGFBI

Introduction: Nearly 50% of patients with pNENs have metastases at the time of initial diagnosis, and there is a lack of effective treatment once they have metastases. The 5-year overall survival rate for G3 pNENs with metastasis at diagnosis was 0, which was significantly lower than that for patients without metastasis, with a 5-year overall survival rate of 43%. At present, the pathogenesis of pNENs has not been clarified.

Conference:

Presenting Author:

Authors: Ye M, Tang Q,

Keywords: RNA methyltransferases, Tumor metastasis, Pancreatic neuroendocrine neoplasm, Transforming growth factor-β-induced gene, Integrin/FAK signaling pathway,

#3893 Pancreatic neuroendocrine tumor associated hypophosphatemia due to tumor-induced osteomalacia – A case report

Introduction: Tumor-induced osteomalacia (TIO) is a rare syndrome characterised by hypophosphataemia and osteomalacia with renal phosphate wasting caused by elevated levels of fibroblast growth factor 23 (FGF23) in the setting of tumor. The primary tumor is typically found in bone or soft tissue.

Conference:

Presenting Author:

Authors: Storan D, Almeamar H, O'Shea D, O'Toole D, Crowley R,

Keywords: pNET, pancreas, hypophosphataemia, osteomalacia, fgf23,